The MDS Foundation proudly partners with the following organizations
The MDS Foundation proudly partners with the following organizations
Phone within the US
1-(800)-637-0839Outside the US only
1-(609)-298-1035Address
The MDS Foundation
228 Park Ave S
PMB 118983
New York
NY 10003-1502
The MDS Foundation is a global nonprofit 501(c)(3) advocacy organization (EIN 22-3283911), supporting patients, families, and healthcare providers in the fields of MDS and related diseases for over 30 years.
© 2024 MDS Foundation. All rights reserved.
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
Latest News
Explore the forefront of MDS research, treatments, and community happenings to stay informed on the ever-evolving landscape of MDS care.
September 26, 2025
Voices of MDS Featured in touchHAEMATOLOGY
The MDS Foundation is proud to share that the Voices of MDS campaign has been highlighted in touchHAEMATOLOGY as part of Blood Cancer Awareness Month.
August 18, 2025
Inside Information: Faron to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA
Faron announced plans to advance bexmarilimab into a registrational Phase 2/3 study in treatment-naïve (frontline) HR-MDS after positive meeting with the FDA.
August 17, 2025
Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA
Ascentage Pharma announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
-800x533.jpg&w=3840&q=75)
August 14, 2025
Share Your Voice, Shape the Future: New Survey Feature Launches on the MDS Exchange
The MDS Foundation is excited to announce the launch of a new survey feature within the MDS Exchange, empowering community members to share their specific experiences in a safe, supportive space, while helping shape future care, resources, and research in myelodysplastic syndromes (MDS).
August 5, 2025
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Sent Biosciences announced it has confirmed the recommended Phase 2 dose (RP2D) in its Phase 1 study of SENTI-202, the Company’s potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML).
July 30, 2025
FARON ANNOUNCES ACCEPTANCE OF BEXMARILIMAB DATA FOR ORAL PRESENTATION AT ESMO 2025
Faron Pharmaceuticals announced that new clinical and translational data from the Phase I/II BEXMAB study evaluating bexmarilimab in combination with azacitidine in higher-risk myelodysplastic syndromes (HR-MDS) will be presented as a part of a Mini Oral Abstract Session at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place from October 17-21, 2025, in Berlin, Germany.
July 28, 2025
Servier Announces Positive Data from Long-Term Follow-Up Analysis of the Phase 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated Acute Myeloid Leukemia
Servier announced that long-term efficacy and safety results, published in Blood Advances, continue to demonstrate the sustained survival benefit of adding TIBSOVO to azacitidine in IDH1-mutated AML.
July 21, 2025
New Study Confirms Safety of Partially Matched Stem Cell Transplants
A new clinical trial shows that using partially matched peripheral blood stem cell (PBSC) donors—combined with cyclophosphamide to prevent graft-versus-host disease (GVHD)—can be a safe and effective option for patients with blood cancers who don’t have fully matched donors. One year post-transplant, 80% of participants were alive, and the rate of serious GVHD was comparable to fully matched transplants. This breakthrough could help more patients, especially those from diverse backgrounds, access life-saving transplants.
